BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 6301800)

  • 1. Review of cannabinoids and their antiemetic effectiveness.
    Vincent BJ; McQuiston DJ; Einhorn LH; Nagy CM; Brames MJ
    Drugs; 1983 Feb; 25 Suppl 1():52-62. PubMed ID: 6301800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics.
    Badowski ME
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):441-449. PubMed ID: 28780725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting.
    Pergolizzi JV; Taylor R; LeQuang JA; Zampogna G; Raffa RB
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):467-477. PubMed ID: 28235999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
    Frytak S; Moertel CG; O'Fallon JR; Rubin J; Creagan ET; O'Connell MJ; Schutt AJ; Schwartau NW
    Ann Intern Med; 1979 Dec; 91(6):825-30. PubMed ID: 517882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.
    Lile JA; Kelly TH; Hays LR
    Drug Alcohol Depend; 2011 Jul; 116(1-3):86-92. PubMed ID: 21227600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
    Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
    Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
    Tramèr MR; Carroll D; Campbell FA; Reynolds DJ; Moore RA; McQuay HJ
    BMJ; 2001 Jul; 323(7303):16-21. PubMed ID: 11440936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiemetic Effects of Cannabinoid Agonists in Nonhuman Primates.
    Wooldridge LM; Ji L; Liu Y; Nikas SP; Makriyannis A; Bergman J; Kangas BD
    J Pharmacol Exp Ther; 2020 Sep; 374(3):462-468. PubMed ID: 32561684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew).
    Kwiatkowska M; Parker LA; Burton P; Mechoulam R
    Psychopharmacology (Berl); 2004 Jul; 174(2):254-9. PubMed ID: 14740147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid.
    Feigenbaum JJ; Richmond SA; Weissman Y; Mechoulam R
    Eur J Pharmacol; 1989 Oct; 169(1):159-65. PubMed ID: 2557222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of cannabinoids in CNS disease.
    Croxford JL
    CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoids in clinical practice.
    Williamson EM; Evans FJ
    Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.
    Einhorn LH; Nagy C; Furnas B; Williams SD
    J Clin Pharmacol; 1981; 21(S1):64S-69S. PubMed ID: 6271844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
    Darmani NA; Johnson JC
    Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta-9-tetrahydrocannabinol as an antiemetic.
    Anderson PO; McGuire GG
    Am J Hosp Pharm; 1981 May; 38(5):639-46. PubMed ID: 6269423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
    McCabe M; Smith FP; Macdonald JS; Woolley PV; Goldberg D; Schein PS
    Invest New Drugs; 1988 Sep; 6(3):243-6. PubMed ID: 2847994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics.
    May MB; Glode AE
    Cancer Manag Res; 2016; 8():49-55. PubMed ID: 27274310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
    Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Rosenberg SA
    Cancer; 1981 Apr; 47(7):1746-51. PubMed ID: 6261926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.
    Orr LE; McKernan JF
    J Clin Pharmacol; 1981; 21(S1):76S-80S. PubMed ID: 6271846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.